NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
Clinical Trials
13 trialsNCT04890236 2025-01-20
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Emory University
Phase EARLY_PHASE1 Completed
NCT06101381 2024-12-09
CARTHEDRALL
University of Sao Paulo
Phase 1/2 Recruiting
NCT04778579 2024-06-26
CART19-BE-02
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Phase 2 Active not recruiting
NCT03896854 2023-11-29
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT01029366 2023-06-22
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
University of Pennsylvania
Phase 1 Completed
NCT02030834 2023-06-22
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
University of Pennsylvania
Phase 2 Completed
NCT02529813 2022-06-30
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01551043 2020-07-09
Allo CART-19 Protocol
University of Pennsylvania
Phase 1 Terminated
NCT01626495 2020-03-23
Pedi CART19
University of Pennsylvania
Phase 1/2 Completed
NCT03101709 2017-04-05
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Henan Cancer Hospital
Phase 1 Unknown
NCT03027739 2017-01-23
CCFMPCA
Fujian Medical University
Phase 2/3 Unknown
NCT02810223 2016-10-14
Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Beijing Sanwater Biological Technology Co., Ltd.
Phase 1 Unknown